Another study conducted at MD Anderson Cancer Center evaluated the degree of toxicity and antitumor activity in the delivery of Ad-P53 gene therapy via bronchoscopic intratumoral injection in 12 patients with endobronchial NSCLC and expressing a P53 gene mutation [185]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.